United States· US:82497-132_ef8eef01-b278-484e-b4d4-85905e756674
Rolvedon
A eflapegrastim product containing eflapegrastim, registered in United States by Assertio Specialty Pharmaceuticals, LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- EFLAPEGRASTIM
- Manufacturer
- Assertio Specialty Pharmaceuticals, LLC
- Country
- United States (US)
- ATC code
- L03AA19
- ATC class
- Eflapegrastim
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1182497-132-01
- ndc118249713201.6 mL in 1 SYRINGE, GLASS (82497-132-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L03AA19
Eflapegrastim, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5d5e2db9-7b2f-46c0-a0ee-2a46858f371e GET /v1/drugs/5d5e2db9-7b2f-46c0-a0ee-2a46858f371e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "13.2",
"substance": "EFLAPEGRASTIM",
"productndc": "82497-132",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/.6mL",
"application_number": "BLA761148",
"marketing_category": "BLA"
}See everything about eflapegrastim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.